$1.37-0.03 (-2.14%)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States.
Bone Biologics Corporation in the Healthcare sector is trading at $1.37 with a market capitalization of $3M. Wall Street consensus targets $22.20 (1 analysts), implying a +1520.4% move over the next 12 months. The stock is currently near its 52-week low of $1.05, remaining 14.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$805,054β | -$733,105β | -$715,274β | -$748,075β | -$1.04M |
| Net Income | -$765,988β | -$684,643β | -$666,737β | -$740,519β | -$1.02M |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which ...